Lupin Ltd (Lupin) undertakes the manufacture and marketing of generic and branded pharmaceutical products and active pharmaceutical ingredients (APIs). The company focuses on therapeutic areas such as generics, biosimilars, specialty, over-the-counter, active pharmaceutical ingredients, global institutional business, and tech-driven offerings. Its product portfolio is focused on various therapeutic areas such as cardiovascular, diabetes, asthma, respiratory diseases, pediatrics, oncology, immunology, metabolic disorders, central nervous system, gastrointestinal, tuberculosis, infections, and non-steroidal anti-inflammatory drugs.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lupin is focused on delivering advanced, accessible, and impactful healthcare solutions through its research and development (R&D) initiatives. The company invests in developing differentiated, high-quality medicines to improve patient outcomes and support sustainable healthcare systems. Lupin's R&D strategy is aligned with its portfolio strategy, emphasizing APIs, complex generics, inhalation, injectable, ophthalmic, and oral segments. The company aims to advance biosimilar research and new chemical entities, particularly in oncology, immunology, and metabolic disorders, to address unmet patient needs globally. Lupin's R&D units are located in India (Pune and Aurangabad), the US (New Jersey and Florida), Mexico, Brazil, and the Netherlands. These units are responsible for addressing complex scientific challenges, developing new products, and ensuring quality and regulatory compliance. The Intellectual Property Management Group (IPMG) manages the creation, securing, and leveraging of advanced research to build a high-value portfolio of patents and pipeline products. As of March 2026, the company filed 41 products and received 52 approvals, and has now 742 cumulative filings and 584 cumulative approvals. It also had 44 formulations, 16 API's, in FY2026; and five formulations and 81 new chemical entity applications and patents secured. As of March 2026, the company had 924 active patent applications and 444 ANDAs and NDAs filed with the US FDA. In FY2026, the company spent INR20,631 million on R&D, which as a percentage of revenue, stood at 7.3% and grew 16.7% YoY.